Home›Articles›The trial that earned ripretinib its narrow fourth-line approvalArticleThe trial that earned ripretinib its narrow fourth-line approvalArticlesConnectionsSourcesComments (0)Reader Challenges (0)ConnectionsArticle OnRipretinib, Drugs and Medicinal Substances Well-attested SourcesRipretinib (Wikipedia)History section, trial design sentenceQuote, History section, trial design sentenceThe approval of ripretinib was based on the results of an international, multi-center, randomized, double-blind, placebo-controlled clinical trial (INVICTUS/NCT03353753) that enrolled 129 participants with advanced gastrointestinal stromal tumor (GIST) who had received prior treatment with imatinib, sunitinib, and regorafenib.View the SourceMedicine Atlas Original Articlestier 1Comments (0)No comments yet. Be the first to share a thought.Sign in to join the discussion.Reader Challenges (0)No disputes yet. Spotted an error or a better source? Open the first one.Sign in to dispute this or suggest a correction.